Prostate cancer is the most commonly diagnosed non-skin cancer in Canadian men, with an estimated 26,500 new cases in 2012. Current treatment options for castration-resistant prostate cancer offer only a 6-8 month increase in overall survival. This project’s goal was to identify compounds that inhibit the function of CBX7, a protein implicated in castration-resistant prostate cancer, with the ultimate goal of creating a novel treatment. The project established a CBX7 assay and tested potential inhibitors that they designed using multiple computational approaches.